The ICIs used in NSCLC target the programmed death 1 (PD-1) receptor, the programmed death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA4). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.